RBC Capital analyst Gregory Renza raised the firm’s price target on Spruce Biosciences to $9 from $8 and keeps an Outperform rating on the shares after meeting with its management head of the CAHmelia-203 and CAHptain-205 topline readouts in March. The firm remains optimistic, with views bolstered by tildacerfont data to-date and the management’s conviction, also noting that its clear points of class differentiation should serve tildacerfont well in the long term, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRB:
- Guggenheim optimistic ahead of readouts, starts Spruce Biosciences at Buy
- Spruce Biosciences initiated with a Buy at Guggenheim
- Spruce Biosciences: enrollment in CAHmelia-204 study for CAH complete
- Spruce Biosciences: Cash equivalents as of December 31 $96M
- Spruce to report results of CAHmelia-203 and CAHptain-205 in March 2024